VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (NCT04654052) | Clinical Trial Compass
Active — Not RecruitingPhase 4
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome
Spain634 participantsStarted 2021-07-02
Plain-language summary
The objective of the study is to establish a de-scaling strategy of P2Y12 inhibitors (P2Y12 i) with a decrease in hemorrhagic events without increasing ischemic complications based on a Platelet Function Test (PFT).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with age 18 years or above.
* Patient is able to understand the nature of study and has provided written informed consent.
* Patients with Acute Coronary Syndrome and who underwent PCI during the admission, who have been discharged on double. antiplatelet therapy with Acetylsalicylic Acid and Ticagrelor or Prasugrel.
Exclusion Criteria:
* Patients with history of intracranial bleeding.
* Patients with contraindication for the use of Acetylsalicylic Acid or Clopidogrel or Ticagrelor or Prasugrel.
* Patients with major ischemic or hemorrhagic events during the first month.
* Patients with Thrombocytopenia \<50,000 /µL.
* Patients with permanent oral anticoagulation.
* Patient is pregnant or breast feeding.
* Patients with impossibility to complete 1 year of follow-up.
* Patient´s life-expectancy is less than 24 months.